AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03435159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Instrumental Chiropractic Spinal Manipulation
Description: Activator technique was applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Instrumental spinal manipulation was applied with Activator V chiropractic instrument. For C1 vertebra, the procedure was applied in supine position, by placing the Activator device horizontally on the participant's atlas transverse process of the affected side and applying a pushing force in the medial direction.~For C2 vertebra, the procedure was applied in prone position, by placing the Activator device in the relevant C2 pedicle-lamina junction of the participant's affected side and applying a pushing force in the anterior, superior and mild medial direction of movement of the facet joint.
Study NCT03634722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHENIX4-8-8 PLUS
Description: transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
Study NCT03581669 — intervention group
Intervention type: DEVICE
Intervention: Cerclage and total hip arthroplasty
Description: acetabular fractures in the elderly treated with cerclage acetabulum and total hip arthroplasty
Study NCT03772093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trabert current
Description: Trabert current is an interrupted direct current of low frequency (143 Hz) applied via medium sized electrodes supported on a thick moist viscose sponge. These electrodes are placed near the spinal column along the thoracolumbar region. The electrodes are separated from each other by a distance of 3-4 cms.The current is passed through electrodes placed on the body. The intensity of the current is gradually increased short of pain. The feeling should be a pronounced but a comfortable 'tingling' sensation ('comfortably strong'). By doing this, the optimum current strength specific to the patient is found. The intensity of the current is slowly increased in the first few minutes as patients get used to the sensation. It is thought that this current provides pain relief, reduces muscle spasm and increases blood flow.
Study NCT03772093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual massage
Description: Therapeutic massage is the manipulation of the soft tissue of whole body areas to bring about generalised improvements in health.Massage is thought to work through a mechanical action and a reflex action. A mechanical action is created by moving the muscles and soft tissues of the body using pressure and stretching movement. This mechanical action is based on breaking up fibrous tissue and loosen stiff joints.It may help heal damaged muscle, stimulate circulation, clear waste products via the lymphatic system, boost the activity of the immune system, reduce pain and tension and induce a calming effect.
Study NCT04626700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNAP
Description: iNAP for the treatment of OSA
Study NCT04626700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP for the treatment of OSA
Study NCT02163317 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo MRI-guided focal SRS
Study NCT02163317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo staging MRI with contrast
Study NCT02163317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
Study NCT02163317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum Prostate Antigen Test
Description: Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
Study NCT02163317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Exam
Description: Exam of rectal health. Performed every three months for up to two years throughout the study.
Study NCT01555398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions
Description: The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
Study NCT01555398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions
Description: The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
Study NCT02690337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1123
Description: starting intravenous (IV) dose of 0.1 mg/kg.
Study NCT02163317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Prostate Cancer Index Composite
Description: This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
Study NCT04265300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creative Roots
Description: The Creative Roots beverage is a coconut water-based drink with three flavors Mixed Berry, Watermelon Lemonade, and Peach Mango. The ingredients are as follows and are the same for all three flavors: water, coconut water concentrate, citric acid, stevia leaf extract, natural flavor, rosemary extract (to preserve flavor). Contains: coconut
Study NCT03633864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
Study NCT03370185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
Study NCT01648998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: single dose 500 mg, capsule
Study NCT03055546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration of oxytocin
Study NCT03055546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal administration of placebo
Study NCT02595606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% Sodium Hyaluronate
Description: five times per day for the intervention of eye drop
Study NCT00763594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Relational Therapy
Description: 16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
Study NCT00763594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Relational Therapy
Description: 16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
Study NCT00763594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: 16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
Study NCT02399397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial blood sampling
Description: Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
Study NCT02399397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial blood sampling
Description: Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
Study NCT02399397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Train of four monitoring
Description: Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
Study NCT02399397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Train of four monitoring
Description: Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
Study NCT02399397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood testing for liver and renal function
Description: Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
Study NCT02399397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood testing for liver and renal function
Description: Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
Study NCT02399397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
Study NCT02399397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
Study NCT02399397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small to medium sized surgery under general anesthesia
Description: Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
Study NCT02399397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small to medium sized surgery under general anesthesia
Description: Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
Study NCT03828188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Ginseng Concentrated Powder
Description: Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.
Study NCT03828188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 12 weeks.
Study NCT01648998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01885663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood therapy
Description: Intravascular umbilical cord blood therapy
Study NCT03627715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propagermanium
Description: Immediate release capsule
Study NCT01485107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System
Description: Focused ultrasound energy delivered below the surface of the skin.
Study NCT04423419 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PENG block
Description: The US probe placed in a transverse plane over the AIIS . the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic drug was injected while observing for adequate fluid spread for a total volume of 20 mL of Bupivacain 0.25%
Study NCT04423419 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fascia iliaca block
Description: ultrasound guidance landmarks are the anterior superior iliac spine and the pubic tubercle (inguinal ligament). The injection site along the lateral one-third of aline joining the anterior superior iliac spine (ASIS) and pubic tubercle (PT) targeting the compartment between fascia iliaca and fascia lata ,the total volume of injection is 20ml of Bupivacain 0.25%
Study NCT04423419 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IV analgesia
Description: IV analgesia
Study NCT04268056 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of skin culture samples
Description: Collection of skin culture samples using a sterile swab. the swab will gently rubbed on the skin on the 3 different skin areas. The target areas are i) regions surrounding the RT treatment area (if possible, not from the scar area or from skin folds areas), ii) a control site of the normal (healthy) breast , iii) a control area on the forehead.
Study NCT01813305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSTC1
Description: vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
Study NCT01813305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CSTC1 Matched vehicle
Study NCT03702387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard intravenous regional anesthesia (IVRA) with reapplication of esmach
Description: his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
Study NCT01299142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGI-101-1A6
Description: anti-TSG101 human monoclonal antibody, single dose
Study NCT01299142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FGI-101-1A6
Description: anti-TSG101 human monoclonal antibody, single dose
Study NCT01368237 — intervention group
Intervention type: RADIATION
Intervention: Computed tomography scan
Description: Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
Study NCT04460833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback modalities given through an augmented reality headset
Description: All children wear the augmented reality headset. After a habituation period to the holograms, they start the protocol. It consists of a warm-up session, training session (which three feedback modalities are presented), calibration session (to get the maximal speed and spontaneous speed of the child), and test session. During test session, all the children walk on the 30m corridor. They have 6 feedback modalities + the control, given randomly. On the way out, they have to walk fast as possible ; on the return they have to walk at intermediate speed.
Study NCT03421639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH analog (11.25mg Leuprolide acetate)
Description: 11.25 Leuprolide acetate only one administration
Study NCT03421639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor and GnRH analog
Description: 1mg/day of Anastrazole for 3 months
Study NCT03421639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase and GnRH analog (11.25mg Leuprolide acetate)
Description: Leuprolide acetate 11.25mg only one
Study NCT01642433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 3x daily
Study NCT01642433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Prazosin medication, 3x daily dosing, up to 15mg/day
Study NCT02832349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Actions
Description: Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
Study NCT00652509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Dialogue to Educate and Activate (IDEA)
Description: IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
Study NCT00652509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Education (IE)
Description: IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
Study NCT01696786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte cryopreservation
Description: Oocyte (egg) cryopreservation (freezing) to preserve fertility
Study NCT03001622 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IFX-1
Description: chimeric, monoclonal antibody
Study NCT03512197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin was provided as 25 mg capsules 8PC, was supplied as double-blind in blister packs and taken orally.
Study NCT03512197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.
Study NCT03512197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
Study NCT03627715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule
Study NCT02118350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mat Pilates Training
Description: Mat Pilates training performed two times at week for 16 weeks.
Study NCT03512197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
Study NCT04865692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFRT
Description: Patients of Interventional group were treated with routine physiotherapy program combined with LI-BFR consist of 10 minutes' session 3 per week for 12 weeks. In order to determine the training load 20% of 1RM, participants had performed knee extension in full range with a challenging weight. After each test, participants rated their perceived exertion level on (RPE) scale to determine the difficulty of the resistance. The derived 1RM was used to determine the 20% 1RM load used for low-load training. Blood flow restriction proximal to the working muscles achieved through using pressure cuffs. The cuff was applied to the proximal thigh. During week 1 the inflation pressure was 100mmHg. Final exercise pressure based the week of the training. Quadriceps size was measured by tape measures thigh
Study NCT03011437 — intervention group
Intervention type: OTHER
Intervention: Esophagogastroduodenoscopy
Description: Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
Study NCT02190721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tbo-filgrastim
Description: 5 μg/kg
Study NCT04865692 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Physical Therapy
Description: knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
Study NCT03557814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED appliance during mechanical debridement
Description: Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
Study NCT03557814 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LED appliance after mechanical debridement
Description: Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
Study NCT03557814 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mechanical debridement alone
Description: Mechanical debridement by periodontal curets alone
Study NCT04046263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucroferric Oxyhydroxide Chewable Tablet
Description: Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal
Study NCT04425811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiological taping
Description: The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
Study NCT04425811 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: kinesiological taping
Description: The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
Study NCT01054313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere)
Description: Starting dose 30 mg/m\^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
Study NCT01054313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (Rapamycin)
Description: Starting dose 1 mg daily by mouth 1 time a day.
Study NCT01054313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth twice a day with prostate cancer.
Study NCT04663854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trehalose
Description: Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.